BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23758804)

  • 1. The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection.
    Lee CW; Kuo WL; Yu MC; Chen TC; Tsai CN; Lee WC; Chen MF
    World J Surg Oncol; 2013 Jun; 11(1):136. PubMed ID: 23758804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor.
    Zhuang PY; Zhang JB; Zhu XD; Zhang W; Wu WZ; Tan YS; Hou J; Tang ZY; Qin LX; Sun HC
    Cancer; 2008 Jun; 112(12):2740-8. PubMed ID: 18412155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
    Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
    PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma.
    Xiang ZL; Zeng ZC; Tang ZY; Fan J; Sun HC; Tan YS
    Mol Biol Rep; 2011 Jun; 38(5):3531-9. PubMed ID: 21104440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection.
    Jin Y; Liang ZY; Zhou WX; Zhou L
    J Invest Surg; 2018 Oct; 31(5):412-419. PubMed ID: 28758812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
    Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
    Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
    Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
    J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy].
    Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY; Hu WY; Han B
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):753-8. PubMed ID: 23291069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CK19 Predicts Recurrence and Prognosis of HBV Positive HCC.
    Shuyao W; Mingyang B; Feifei M; Xiaoqin H
    J Gastrointest Surg; 2022 Feb; 26(2):341-351. PubMed ID: 34506016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.
    Qin SD; Zhang J; Qi YP; Zhong JH; Xiang BD
    World J Surg Oncol; 2022 Jun; 20(1):209. PubMed ID: 35725470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma.
    Chung GE; Lee JH; Yoon JH; Myung SJ; Lee K; Jang JJ; Lee JM; Kim SH; Suh KS; Kim YJ; Lee HS
    Abdom Imaging; 2012 Jun; 37(3):439-46. PubMed ID: 21584634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nuclear accumulation of CXCR4 and overexpressions of VEGF-C and CK19 are associated with a higher risk of lymph node metastasis in hepatocellular carcinoma].
    Xiang ZL; Zeng ZC; Tang ZY; Fan J; Sun HC; Wu WZ; Tan YS
    Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):344-9. PubMed ID: 20723431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Xiaohong S; Huikai L; Feng W; Ti Z; Yunlong C; Qiang L
    World J Surg; 2010 May; 34(5):1028-33. PubMed ID: 20174806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.
    Lee JI; Lee JW; Kim JM; Kim JK; Chung HJ; Kim YS
    World J Gastroenterol; 2012 Sep; 18(34):4751-7. PubMed ID: 23002345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.
    Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK
    World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.
    Yamashita S; Vauthey JN; Kaseb AO; Aloia TA; Conrad C; Hassan MM; Passot G; Raghav KP; Shama MA; Chun YS
    J Gastrointest Surg; 2016 Oct; 20(10):1725-31. PubMed ID: 27456016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma.
    Shin E; Yu YD; Kim DS; Won NH
    Pathol Oncol Res; 2014 Jul; 20(3):667-75. PubMed ID: 24619866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma.
    Lee CW; Lin SE; Tsai HI; Su PJ; Hsieh CH; Kuo YC; Sung CM; Lin CY; Tsai CN; Yu MC
    Oncol Lett; 2018 Jan; 15(1):559-567. PubMed ID: 29387234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence.
    Uenishi T; Kubo S; Yamamoto T; Shuto T; Ogawa M; Tanaka H; Tanaka S; Kaneda K; Hirohashi K
    Cancer Sci; 2003 Oct; 94(10):851-7. PubMed ID: 14556657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.